<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Significant changes" /><meta name="IX" content="Significant changes" /><title>Significant changes: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP53-significant-changes.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP53-significant-changes.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP53-significant-changes.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP3-general-information-and-changes-for-this-edition.htm">General information and changes for this edition</a> &gt; <a href="PHP52-changes-for-this-edition.htm">Changes for this edition</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP52-changes-for-this-edition.htm" title="Previous: Changes for this edition">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP54-dose-changes.htm" title="Next: Dose changes">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>BNF for Children</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP10928-significant-changes.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Significant changes</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; General information and changes for this edition &gt; Changes for this edition</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>Significant changes</h1><?highlighter on?><div id="pC" class="jN"><p> Significant changes have been made in the following sections for BNF No. 64:</p><p>The spelling of the stem 'sulph' has been amended to'sulf' throughout <em>BNF </em> to reflect the monographs of the British Pharmacopoeia 2012</p><p>Paracetamol poisoning [updated advice on management], <a title="Paracetamol poisoning management" href="PHP188-analgesics-non-opioid.htm#PHP191">Emergency Treatment of Poisoning</a></p><p>Proton pump inhibitors [increased risk of fractures with long-term use], <a title="1.3.5 Proton pump inhibitors" href="PHP431-proton-pump-inhibitors.htm">section 1.3.5</a></p><p>Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation [NICE guidance], <a title="Dabigatran etexilate" href="PHP1503-dabigatran-etexilate.htm">section 2.8.2</a></p><p>Apixaban for the prevention of venous thromboembolism after total hip or knee replacement [NICE guidance], <a title="Apixaban" href="PHP1507-apixaban.htm">section 2.8.2</a></p><p>Rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation [NICE guidance], <a title="Rivaroxaban" href="PHP1511-rivaroxaban.htm">section 2.8.2</a></p><p>Roflumilast for the management of severe chronic obstructive pulmonary disease [NICE guidance], <a title="Roflumilast for the management of severe chronic obstructive pulmonary disease" href="PHP1891-phosphodiesterase-type-4-inhibitors.htm#PHP18463">section 3.3.3</a></p><p>Adrenaline auto-injectors for anaphylaxis [brand prescribing recommended], <a title="Intramuscular injection for self-administration (Respiratory system)" href="PHP1983-intramuscular-injection-for-self-administration.htm#PHP1983-intramuscular-injection-for-self-administration">section 3.4.3</a></p><p>Prevention of secondary case of <em>Haemophilus influenzae</em> type b disease, <a title="Prevention of secondary case of Haemophilus influenzae  type b disease" href="PHP3281-prevention-of-secondary-case-of-haemophilus-influenzae-type-b-disease.htm">section 5.1, Table 2</a></p><p>HIV infection [initiation of treatment], <a title="5.3.1 HIV infection" href="PHP3743-hiv-infection.htm">section 5.3.1</a></p><p>Exenatide modified-release for the treatment of type 2 diabetes [NICE guidance], <a title="6.1.2.3 Other antidiabetic drugs" href="PHP4173-other-antidiabetic-drugs.htm">section 6.1.2.3</a></p><p>Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis [MHRA/CHM advice], <a title="Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis" href="PHP5450-cetuximab.htm#PHP18413">section 8.1.5</a></p><p>Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy [NICE guidance], <a title="Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012) NICE guidance" href="PHP5450-cetuximab.htm#PHP18395">section 8.1.5</a></p><p>Eribulin for the treatment of locally advanced or metastatic breast cancer [NICE guidance], <a title="Eribulin" href="PHP5466-eribulin.htm">section 8.1.5</a></p><p>Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia [NICE guidance], <a title="Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)" href="PHP5514-protein-kinase-inhibitors.htm#PHP18379">section 8.1.5</a></p><p>Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance [NICE guidance], <a title="Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)" href="PHP5514-protein-kinase-inhibitors.htm#PHP18380">section 8.1.5</a></p><p>Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen [NICE guidance], <a title="Cabazitaxel NICE guidance" href="PHP5550-taxanes.htm#PHP18374">section 8.1.5</a></p><p>Oral tacrolimus products: prescribe and dispense by brand name only, to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection [MHRA/CHM advice], <a title="prograf MHRA/CHM advice dec 08" href="PHP5639-tacrolimus.htm#PHP5640">section 8.2.2</a></p><p>Rituximab for the first-line treatment of stage III-IV follicular lymphoma [NICE guidance], <a title="Rituximab NICE guidance (a)" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#PHP5652">section 8.2.3</a></p><p>Fingolimod: not recommended for patients at known risk of cardiovascular events. Advice for extended monitoring for those with significant bradycardia or heart block after the first dose [MHRA/CHM advice], <a title="MHRA/CHM advice Fingolimod: not recommended for patients at known risk of cardiovascular events. Advice for extended monitoring for those with significant bradycardia or heart block after the first dose (May 2012)" href="PHP5700-fingolimod.htm#PHP18410">section 8.2.4</a></p><p>Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis [NICE guidance], <a title="Fingolimod" href="PHP5700-fingolimod.htm">section 8.2.4</a></p><p>Tocilizumab for the treatment of rheumatoid arthritis [NICE guidance updated], <a title="Tocilizumab for the treatment of rheumatoid arthritis (February 2012)" href="PHP6607-cytokine-modulators.htm#PHP18498">section 10.1.3</a></p><p>Tocilizumab for the treatment of systemic juvenile idiopathic arthritis [NICE guidance], <a title="NICE guidance: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis" href="PHP6607-cytokine-modulators.htm#PHP18472">section 10.1.3</a></p><p>Febuxostat: serious hypersensitivity reactions [MHRA/CHM advice], <a title="MHRA/CHM advice Febuxostat: stop treatment if signs or symptoms of serious hypersensitivity (e.g. serious skin reactions or systemic hypersensitivity) occur " href="PHP6673-febuxostat.htm#PHP18479">section 10.1.4</a></p><p>Ranibizumab and pegaptanib for the treatment of age-related macular degeneration [NICE guidance updated], <a title="Ranibizumab and pegaptanib NICE guidance" href="PHP7164-subfoveal-choroidal-neovascularisation.htm#PHP7166">section 11.8.2</a></p><p>Haemophilus type b conjugate vaccine [invasive <em>Haemophilus influenzae</em> type b disease], <a title="Haemophilus type b conjugate vaccine" href="PHP8283-haemophilus-type-b-conjugate-vaccine.htm">section 14.4</a></p><p>Changes to drug interactions [new or amended drug entries will no longer be underlined in print versions], <a title="A1 Interactions" href="PHP8848-interactions.htm">Appendix 1</a></p></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP52-changes-for-this-edition.htm">Previous: Changes for this edition</a> | <a class="top" href="PHP53-significant-changes.htm#">Top</a> | <a accesskey="]" href="PHP54-dose-changes.htm">Next: Dose changes</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>